Joseph Miller compensation by year
Avalo Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
| Salary | $153,600 | $356,000 | $116,748 |
| Bonus | $61,370 | $222,000 | $0 |
| Stock awards | $202,500 | $0 | $0 |
| Option awards | $255,515 | $592,598 | $0 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $0 | $0 | $115,521 |
| Total | $672,985 | $1,170,598 | $232,269 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Avalo Therapeutics, Inc. DEF 14A filed April 27, 2021, accession 0001628280-21-007742, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Avalo Therapeutics, Inc. filed document, accession 0001628280-21-007742. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 25,000 | — | $2.51 |
| Option | 41,563 | — | $4.50 |
| Option | 102,083 | — | $6.22 |
| RSU | 22,500 | — | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Avalo Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.
Avalo Therapeutics’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Michael Cola | Former Chief Executive Officer and former principal executive officer | $3,820,306 |
| Garry Neil | Chief Scientific Officer | $2,688,804 |
| H. Jeffrey Wilkins | Former Chief Medical Officer | $1,487,778 |
| Joseph Miller · this page | Former Chief Financial Officer, former principal financial officer, and former principal executive officer | $232,269 |
Board service
Avalo Therapeutics board · FY2021–FY2022| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2022 | $8,242 | — | $10,000 | $0 | $18,242 |
| FY2021 | $0 | — | $138,421 | $0 | $138,421 |
Each year as the company reported it in Avalo Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Avalo Therapeutics pays directors a $40,000 cash retainer and $20,100 in Options. As stated in Avalo Therapeutics's FY2025 proxy.
The full Avalo Therapeutics compensation record
free company briefThis page is one person within Avalo Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Avalo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.